Stomach cancer showdown: surgery or chemo first?

NCT ID NCT01717924

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the best way to treat a rare and aggressive stomach cancer called signet ring cell adenocarcinoma. It compares two strategies: starting with surgery or starting with chemotherapy before surgery. About 314 patients will take part to see which approach helps people live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

chemotherapy (peri-operative)

What this could lead to

If it works, this could show that starting with chemotherapy improves survival for people with this rare stomach cancer.

What could go wrong

This is a mid-stage trial, so results are not final. The cancer is rare and aggressive, so even the best approach may have limited success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SIGNET RING CELL GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

signet ring cell gastric adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • General and digestive surgical department, Claude Huriez Hospital, University Hospital

    RECRUITING

    Lille, 59037, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••